Nodality collaborates with its customers to find solutions to the most important challenges in drug discovery and development.
Nodality’s core technology, an innovative and proprietary multiparametric flow cytometry-based platform called Single Cell Network Profiling (SCNP™), provides robust human cell-based translational models of disease, drug action and patient-specific response.
For Nodality’s customers, the SCNP platform answers questions that have remained unanswered by other technologies. The analysis is carried out on a custom multiplexed assay platform that enables the simultaneous observation of functional signaling in all relevant cell types in one well. The platform allows for ex vivo modulation of cells from human samples by activators and/or inhibitors of disease relevant pathways to reveal short and long-term cellular responses.
Customers benefit from unprecedented insights into disease biology and characterization of drugs at the single cell level. In addition to its innovative SCNP platform, Nodality offers extensive R&D capabilities, robust experience with disease biology, and industry-leading strengths in informatics and data analysis. When combined, Nodality’s platform and services provide solutions to the drug development industry’s most pressing challenges.
Current drug R&D strategies often fall short in complex diseasesPharmaceutical R&D remains challenged in producing new treatments for many of our most intractable diseases:
- Hematologic Cancers
- Solid Tumors
- Rheumatic Disease
- Gastrointestinal Disease
- Additional Autoimmune Disorders (Celiac, Psoriasis)
- Diseases of the central nervous system
The need to direct the right therapy to the right patient is now widely accepted; however, critical insights required to enable effective patient stratification are lacking. Many current approaches provide little or no information on single-cell processes and cell-cell interactions that define disease biology.
Disruptive advances in modeling human disease are needed, since the old paradigms of target-based discovery, animal-based translational models, and all-comer development strategies are often insufficient.
|R&D Breakthroughs Demand Higher Levels of Biological Understanding|
|Nodality’s Approach||Alternative Technologies|
|Dynamic – Real-time information on cell-cell interactions||Static – Only detects a previous point in time|
|Maps the System – Reveals network function throughout the cell||Limited protein set – Mostly confined to surface proteins|
|Able to identify rare cells||Misses cell subsets|
|Functional – Captures consequences of genomic differences||Interrogate only at the transcriptional/expression level|
|Standardized, quantifiable and reproducible||Lack sufficient rigor|
|High level of resolution – Analysis at the level of single cells||Averages mixed cell populations|
|Multiplexed – Multiple cell subsets and intracellular readouts interrogated simultaneously in a single well||Requires purification of cell subsets|
Nodality’s proprietary SCNP platform bridges the gaps
SCNP – Single Cell Network Profiling – bridges gaps left by traditional approaches by unlocking the highly complex cellular interactions of human disease.
The value of SCNP is demonstrated in the ability to be tuned to monitor critical parameters – such as efficacy, safety and/or toxicity – and can be applied to early target validation, drug optimization, IND candidate selection and patient triage in the clinic. A particular strength of SCNP is the ability to test drug combinations in a human system, to detect both synergies and toxicities early. This is especially useful in indications where animal models are insufficient.
Creation of value by SCNP has been demonstrated across diverse therapeutic landscapes and throughout the full drug discovery and development process. Collaborations have focused on autoimmune disease and immunomodulatory drug candidates. Nodality has also successfully developed stratification diagnostics and immuno-oncology applications.